Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses (SAFE-T)
|ClinicalTrials.gov Identifier: NCT02105506|
Recruitment Status : Completed
First Posted : April 7, 2014
Last Update Posted : April 24, 2015
Rationale: The construction of esophageal anastomoses is associated with considerable risk at postoperative anastomotic leakage. Application of TachoSil®, a tissue sealant with human fibrinogen and thrombin, can improve strength of the esophageal anastomosis and potentially prevent anastomotic leakage.
Objective: Evaluation of feasibility and safety of TachoSil® application on esophageal anastomoses.
Study design: Non-randomized, non-blinded, single-center intervention study. Study population: Patients, 18-80 years old, undergoing an elective total gastrectomy with an esophago-jejunostomy or esophagectomy with a planned esophagogastric anastomosis will be enrolled. A total number of 15 patients will be included in the study.
Intervention: Gastric or esophageal resection will be executed according to the common procedures used in the UMC Utrecht. After construction of the esophageal anastomosis, all enrolled participants will receive a TachoSil® patch, which will be applied on the esophageal anastomosis intra-operatively. Hence, TachoSil® is used as an add-on therapy. TachoSil® will be degraded enzymatically in a period of approximately 24 weeks after application.
Main study parameters/endpoints: The primary endpoint is feasibility, which is assessed by evaluation of adherence of the patch. A time-action analysis of the application of the Tachosil patch will be performed.
Nature and extent of the burden associated with participation: The burden for the patient is minimal. The total surgical procedure will be prolonged with 10-15 minutes. Postoperative care and outpatient visits do not differ from regular protocol. TachoSil® is approved and registered for supportive treatment in surgery for improvement of haemostasis and to promote tissue sealing by the European Commission.
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Disease Gastric Disease||Drug: Tachosil patch||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses|
|Study Start Date :||September 2012|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Experimental: Tachosil patch
Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
|Drug: Tachosil patch|
- Feasibility [ Time Frame: Surgical procedure ]The adherence of the Tachosil patch
- all cause mortality [ Time Frame: within the first 30 days (plus or minus 3 days) after surgery ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02105506
|University Medical Center Utrecht|
|Utrecht, Netherlands, 3584 CX|